Doxorubicin-loaded liposome-like particles embedded in chitosan/hyaluronic acid-based hydrogels as a controlled drug release model for local treatment of glioblastoma

Int J Biol Macromol. 2024 Oct;278(Pt 4):135054. doi: 10.1016/j.ijbiomac.2024.135054. Epub 2024 Aug 24.

Abstract

Glioblastoma (GBM) resection and medication treatment are limited, and local drug therapies are required. This study aims to create a hybrid system comprising liposome-like particles (LLP-DOX) encapsulated in chitosan/hyaluronic acid/polyethyleneimine (CHI/HA/PEI) hydrogels, enabling controlled local delivery of doxorubicin (DOX) into the resection cavity for treating GBM. CHI/HA/PEI hydrogels were characterized morphologically, physically, chemically, mechanically, and thermally. Findings revealed a high network and compact micro-network structure, along with enhanced physical and thermal stability compared to CHI/HA hydrogels. Simultaneously, drug release from CHI/HA/PEI/LLP-DOX hydrogels was assessed, revealing continuous and controlled release up to the 148th hour, with no significant burst release. Cell studies showed that CHI/HA/PEI hydrogels are biocompatible with low genotoxicity. Additionally, LLP-DOX-loaded CHI/HA/PEI hydrogels significantly decreased cell viability and gene expression levels compared to LLP-DOX alone. It was also observed that the viability of GBM spheroids decreased over time when interacting with CHI/HA/PEI/LLP-DOX hydrogels, accompanied by a reduction in total surface area and an increase in apoptotic tendencies. In this study, we hypothesized that creating a hybrid drug delivery system by encapsulating DOX-loaded LLPs within a CHI/HA/PEI hydrogel matrix could achieve sustained drug release, improve anticancer efficacy via localized treatment, and effectively mitigate GBM progression for 3D microtissues.

Keywords: Doxorubicin; Drug release; Glioblastoma; Hydrogels, liposome-like particle; Local anti-cancer therapy.

MeSH terms

  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Chitosan* / chemistry
  • Delayed-Action Preparations* / pharmacology
  • Doxorubicin* / administration & dosage
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacology
  • Drug Liberation*
  • Glioblastoma* / drug therapy
  • Glioblastoma* / pathology
  • Humans
  • Hyaluronic Acid* / chemistry
  • Hyaluronic Acid* / pharmacology
  • Hydrogels* / chemistry
  • Liposomes* / chemistry

Substances

  • Hyaluronic Acid
  • Doxorubicin
  • Chitosan
  • Hydrogels
  • Delayed-Action Preparations
  • Liposomes